Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Continue

Publications

Evolving role of magnetic resonance techniques in primary sclerosing cholangitis.

Selvaraj EA. et al, (2019), World journal of gastroenterology, 25, 644 - 658

Factors Associated With Outcomes of Patients With Primary Sclerosing Cholangitis and Development and Validation of a Risk Scoring System.

Goode EC. et al, (2018), Hepatology

A novel prognostic model for transplant-free survival in primary sclerosing cholangitis

de Vries EM. et al, (2018), Gut, 67, 1864 - 1869

Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease.

Muir AJ. et al, (2018), Hepatology

Cost effectiveness of using ursodeoxycholic acid to treat primary biliary cholangitis.

Chapman RW., (2018), Br J Hosp Med (Lond), 79, 460 - 464

A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis.

Kowdley KV. et al, (2018), Hepatology, 67, 1890 - 1902

Editorial: vancomycin - a promising option for the treatment of primary sclerosing cholangitis?

Chapman RW., (2018), Aliment Pharmacol Ther, 47, 1321 - 1322

INTERNATIONAL EXPERIENCE OF VEDOLIZUMAB IN PRIMARY SCLEROSING CHOLANGITIS AND INFLAMMATORY BOWEL DISEASE

Williamson KD. et al, (2018), GASTROENTEROLOGY, 154, S1097 - S1097

NI-0801, an anti-chemokine (C-X-C motif) ligand 10 antibody, in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid.

de Graaf KL. et al, (2018), Hepatol Commun, 2, 492 - 503

A risk prediction score based on magnetic resonance cholangiopancreatography (MRCP) accurately predicts disease progression in patients with primary sclerosing cholangitis (PSC)

Muir AJ. et al, (2017), HEPATOLOGY, 66, 81A - 81A

Quantification of biliary tree volume in patients with PSC using three dimensional (3D) reconstruction of magnetic resonance cholangiopancreatography (MRCP): Clinical associations and prognostic significance

Tempany-Afdhal C. et al, (2017), HEPATOLOGY, 66, 164A - 165A

Radiologic progression in primary sclerosing cholangitis (PSC) by two-dimensional magnetic resonance cholangiopancreatography (MRCP): Prospective data from a randomized controlled trial

Muir AJ. et al, (2017), HEPATOLOGY, 66, 156A - 156A

Th1 and Innate Lymphoid Cells Accumulate in Primary Sclerosing Cholangitis-associated Inflammatory Bowel Disease

Gwela A. et al, (2017), Journal of Crohn's and Colitis, 11, 1124 - 1134

Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis.

Alberts R. et al, (2017), Gut, 67, 1517 - 1524

Are Dominant Strictures in Primary Sclerosing Cholangitis a Risk Factor for Cholangiocarcinoma?

Chapman RW. and Williamson KD., (2017), Current Hepatology Reports, 16, 124 - 129

Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis.

Weismüller TJ. et al, (2017), Gastroenterology, 152, 1975 - 1984.e8

Update on primary sclerosing cholangitis

Chapman R., (2017), Clinical Liver Disease, 9, 107 - 110

norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.

Fickert P. et al, (2017), Journal of hepatology, 67, 549 - 558

Sa1206 Use of Chromoendoscopy Versus White Light Endoscopy for Colorectal Cancer Surveillance in Inflammatory Bowel Disease Patients With Primary Sclerosing Cholangitis Cohort: A Six Year Experience

Hartery K. et al, (2017), Gastrointestinal Endoscopy, 85, AB200 - AB200

Clinical and Translational Outcomes in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Disease Receiving Vedolizumab

Williamson KD. et al, (2017), Gastroenterology, 152, S1186 - S1187

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?